__NUXT_JSONP__("/drugs/Alunacedase_Alfa", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A recombinant, soluble glycosylated form of human angiotensin converting enzyme 2 (rhACE2) with antihypertensive and potential antineoplastic activities. Alunacedase Alfa may normalize ACE2 levels, cleaving angiotensin II to create angiotensin-(1-7) and restoring the function of the renin-angiotensin system (RAS). ACE2, a homolog of ACE1, appears to function as a negative regulator of the RAS system by converting angiotensin II to angiotensin-(1-7), a peptide with actions that counteract the cardiovascular actions of angiotensin II. In addition, angiotensin-(1-7) may inhibit cyclooxygenase 2 (COX-2) and the production of proinflammatory prostaglandins and may activate the angiotensin-(1-7) G protein-coupled receptor Mas, resulting in diminished tumor cell proliferation. ACE2 levels may be reduced in malignancy and diabetes and in liver, cardiovascular and lung diseases.",fdaUniiCode:"FA2I4Z873U",identifier:"C85447",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C29726"],synonyms:["ALUNACEDASE ALFA","APN01",c,"rhACE2 APN01"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAlunacedase_Alfa",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Alunacedase_Alfa","Alunacedase Alfa","2021-10-30T13:46:26.573Z")));